Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Capital Expenditures (2020 - 2026)

Immuneering's Capital Expenditures history spans 7 years, with the latest figure at $79930.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 793.57% to $79930.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $213211.0, a 278.42% increase, with the full-year FY2025 number at $142226.0, up 67.57% from a year prior.
  • Capital Expenditures came in at $79930.0 for Q1 2026, down from $123910.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $393134.0 in Q3 2022, with the low at $2116.0 in Q2 2025.
  • Historically, Capital Expenditures has averaged $81897.6 across 5 years, with a median of $57149.0 in 2023.
  • Biggest five-year swings in Capital Expenditures: soared 3364.96% in 2022 and later plummeted 94.53% in 2024.
  • Year by year, Capital Expenditures stood at $69302.0 in 2022, then skyrocketed by 146.63% to $170918.0 in 2023, then crashed by 94.53% to $9356.0 in 2024, then surged by 1224.39% to $123910.0 in 2025, then plummeted by 35.49% to $79930.0 in 2026.
  • Business Quant data shows Capital Expenditures for IMRX at $79930.0 in Q1 2026, $123910.0 in Q4 2025, and $7255.0 in Q3 2025.